Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) will be reporting earnings this Wednesday after market close.

Baron Funds, an investment management company, released its “Baron Health Care Fund” second-quarter 2025 investor letter. A ...

Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced an expanded ...

LaMontagne will lead the commercial rollout of the company’s groundbreaking early-stage cancer detection test, Certitude.

The Oncodetect test is a highly sensitive, tumor-informed assay that empowers oncologists and patients with critical insights ...

In fact, eight times out of ten, EXAS stock has popped higher in the week following the flashing of the 2-8-D sequence, with a median return of 4.91%. It’s possible, then, that within a week or two, ...

Colonoscopy prevalence increased from 19.5% in 2019 and 17.8% in 2021 to 27.7% in 2023, while stool-based testing increased ...

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that its Oncodetect™ molecular residual disease (MRD) test has received Medicare ...

University research in Wisconsin led to $500 million Third Wave business, screening tests for cancer, including Cologuard ...

Exact Sciences (EXAS) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook gives ...

Following this development, Canaccord Genuity maintained its Buy rating on Exact Sciences, highlighting the long-term growth potential unlocked by the reimbursement decision.